ATC Group: A06AX04 Linaclotide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A06AX04 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A06 Laxatives
3 A06A Laxatives
4 A06AX Other laxatives
5 A06AX04

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code Route Amount Notes
ORAL Oral 0.29 mg

Active ingredients in A06AX04

Active Ingredient

Linaclotide is a Guanylate Cyclase-C receptor agonist (GCCA) with visceral analgesic and secretory activities. Through its action at GC-C, linaclotide has been shown to reduce visceral pain and increase GI transit in animal models and increase colonic transit in humans.

Related product monographs

Document Type Information Source  
 CONSTELLA Hard capsule MPI, EU: SmPC European Medicines Agency (EU)

Medicines in this ATC group

Austria (AT)

Canada (CA)

Croatia (HR)

Estonia (EE)

Finland (FI)

Ireland (IE)

Lithuania (LT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.